Possible in vivo mechanisms involved in photodynamic therapy using tetrapyrrolic macrocycles

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 1, 2011, Pages 53-61

  Filip, A G ^a   Clichici, S ^a   Daicoviciu, D ^a   Ion, R M ^b   Tatomir, C ^c   Rogojan, L ^d   Opris, I ^d   Mocan, T ^a   Olteanu, D ^a   Muresan, A ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CHEMISTRY AND PETROCHEMISTRY ICECHIM   (Romania)

^c Prof I Chiricuta Oncologic Institute   (Romania)

^d District Hospital   (Romania)

Author keywords

Apoptosis; Cytokines; Oxidative stress; Photodynamic therapy; Tetrapyrrolic macrocycles

Indexed keywords

3,5 AMINOLEVULINIC ACID; 5,10,15,20 TETRAKIS(4 METHOXYPHENYL) PORPHYRIN; 5,10,15,20 TETRAKIS(4 METHOXYPHENYL) PORPHYRIN ZINC COMPLEX; CASPASE 3; GELATINASE A; GELATINASE B; GLUTATHIONE; MALONALDEHYDE; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HISTOPATHOLOGY; IN VIVO STUDY; INNATE IMMUNITY; LIPID PEROXIDATION; MALE; MEMBRANE DAMAGE; NONHUMAN; PHOTODYNAMIC THERAPY; RAT; TISSUE LEVEL; WALKER CARCINOMA;

RATTUS; RATTUS NORVEGICUS;

EID: 78751505037     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500140     Document Type: Article

References (38)

1. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 2005; 52: 339-352.
2. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
3. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004; 1704: 59-86.
4. Dellinger M. Apoptosis or necrosis following Photofrin photosensitization: influence of the incubation protocol. Photochem Photobiol 1996; 64: 182-187.
5. Lam M, Oleinick NL, Nieminen AL. Photodynamic therapyinduced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization. J Biol Chem 2001; 276: 47379-47386.
6. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002; 1: 1-21.
7. Pazos MC, Nader HB. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz J Med Biol Res 2007; 40: 1025-1035.
8. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630.
9. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004; 64: 2328-2332.
10. Milanesio ME, Alvarez MG, Yslas EI, Borsarelli CD, Silber JJ, Rivarola V, et al. Photodynamic studies of metallo 5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin: photochemical characterization and biological consequences in a human carcinoma cell line. Photochem Photobiol 2001; 74: 14-21.
11. Alvarez MG, Yslas EI, Rivarola V, Mori G, La Penna M, Silber JJ, et al. Photodynamic effect of 5,10,15,20-tetrakis(4-methoxyphenyl) porphirine (TMP) on Hep-2 cell lines. Molecules 2000; 5: 379-380.
12. Adler AD, Longo FR, Goldmacher J, Assour J, Korsakoff L. A simplified synthesis for meso-tetraphenylporphine. J Org Chem 1967; 32: 476-487.
13. Ion RM. Spectrophotometric study of the photodegradation reaction of the tetra-aryl-porphyrins. The meso-substituent effect. Rev Chim 1993; 44: 431-435.
14. Ion RM. Spectrophotometric study of the photodegradation reaction of the tetra-aryl-porphyrins. The hydroperoxide effect. Rev Chim 1995; 46: 134-137.
15. Ion RM, Mandravel C. The photodegradation reaction of some porphyrins. South Braz J Chem Soc 1997; 5: 111-129.
16. Ion RM, Grigorescu M. The synthesis computation of tetraarylporphyrins. Rev Chim 1997; 48: 324-328.
17. Ion RM, Stirbet A, Mandravel C. The analysis of the porphyrins purity. Rev Chim 2010; 49: 121-123.
18. Ion RM, Badescu V, Garbalau N, Palii S. Spectral considerations of TAPP photoreactivity. Anal Univ Buc 1999; VIII: 35-43.
19. Ion RM, Scarlat F. Metode neconventionale de sinteza a porfirinelor. Rev Chim 2004; 55: 900-904.
20. Anonymous. Guide for the Care and Use of Laboratory Animals Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. Washington: National Academy Press; 1996.
21. Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorometric determination of malonaldehyde. Clin Chem 1991; 37: 1273-1275.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
23. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: 380-385.
24. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234.
25. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977; 83: 346-356.
26. Weibel ER, Gehr P, Cruz-Orive LM, Muller AE, Mwangi DK, Haussener V. Design of the mammalian respiratory system. IV Morphometric estimation of pulmonary diffusing capacity; critical evaluation of new sampling method. Respir Physiol 1981; 44: 39-59.
27. La Penna, Alvarez MG, Yslas EI, Rivarola V, Durantini EN. Photodynamic activity of 5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin on the Hep-2 human carcinoma cell line: effect of light dose and wavelength range. Bioorg Chem 2001; 29: 130-139.
28. Daicoviciu D, Filip A, Ion RM, Clichici S, Decea N, Muresan A. Oxidative photodamages induced by photodynamic therapy with methoxyphenyl porphyrin derivatives in tumor bearing rats. Folia Praga 2010 (in press).
29. Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 1: Photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007; 21: 293-302.
30. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004; 134: 489-492.
31. Lomaestro BM, Malone M. Glutathione in health and disease: pharmacotherapeutic issues. Ann Pharmacother 1995; 29: 1263-1273.
32. Tatar O, Adam A, Shinoda K, Eckert T, Scharioth GB, Klein M, et al. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. Br J Ophthalmol 2007; 91: 1183-1189.
33. Filip A, Clichici S, Muresan A, Daicoviciu D, Tatomir C, Login C, et al. Effects of PDT with 5-aminolevulinic acid and chitosan on Walker carcinosarcoma. Exp Oncol 2008; 30: 212-219.
34. Clichici S, Filip A, Daicoviciu D, Ion RM, Mocan T, Tatomir C, et al. The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin. Acta Physiol Hung 2010; 97: 41-51.
35. Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 2006; 38: 516-521.
36. Reddi E, Segalla A, Jori G, Kerrigan PK, Liddell PA, Moore AL, et al. Carotenoporphyrins as selective photodiagnostic agents for tumours. Br J Cancer 1994; 69: 40-45.
37. Faustino MA, Neves MG, Cavaleiro JA, Neumann M, Brauer HD, Jori G. Meso-tetraphenylporphyrin dimer derivatives as potential photosensitizers in photodynamic therapy. Part 2. Photochem Photobiol 2000; 72: 217-225.
38. Milanesio ME, Moran FS, Yslas EI, Alvarez MG, Rivarola V, Durantini EN. Synthesis and biological evaluation of methoxyphenyl porphyrin derivatives as potential photodynamic agents. Bioorg Med Chem 2001; 9: 1943-1949.